Search

Author/Creator Janssen, Robert S.

1. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Issue 25 (8th June 2021)

Authors:
Awad, Ahmed M.; Ntoso, Adu; Connaire, Jeffrey J.; Hernandez, German T.; Dhillon, Kiranjit; Rich, Lisa; Henderson, Heather; Lynn, Robert; Hyer, Randall N.; Xie, Fang; Erby, Kimberly; Janssen, Robert S.
Journal:
Vaccine
Issue:
Volume 39:Issue 25(2021)
Page Start:
3346
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study. Issue 6 (30th November 2022)

Authors:
Girndt, Matthias; Plüer, Manfred; Dellanna, Frank; Michelsen, Ann K.; Beige, Joachim; Toussaint, Kai; Wehweck, Hubert J.; Koch, Michael; Hafezi Rachti, Syrus; Faust, Justus; Bosselmann, Hans-Peter; Witzke, Oliver; Janssen, Robert S.
Journal:
Human vaccines & immunotherapeutics
Issue:
Volume 18:Issue 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Issue 7 (11th February 2015)

Authors:
Janssen, Julia M.; Heyward, William L.; Martin, J. Tyler; Janssen, Robert S.
Journal:
Vaccine
Issue:
Volume 33:Issue 7(2015)
Page Start:
833
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Issue 7 (11th February 2015)

Authors:
Janssen, Julia M.; Heyward, William L.; Martin, J. Tyler; Janssen, Robert S.
Journal:
Vaccine
Issue:
Volume 33:Issue 7(2015)
Page Start:
833
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Issue 5 (29th January 2018)

Authors:
Adams, Michael; Bolshoun, David; Bruce, Tami; Chuang, Rita; DeSantis, Donna; Fiel, Thomas; Fitzgibbons, William; Francyk, David; Geisberg, Harry; Giep, Son; Godbole, Narendra; Haas, Terry; Halpern, Stephen; Inzerello, Anthony; Jennings, William; Kaiser, Scott; Kay, Jennifer; Kirby, William; Lendi...
Journal:
Vaccine
Issue:
Volume 36:Issue 5(2018)
Page Start:
668
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age. Issue 31 (17th July 2015)

Authors:
Janssen, Julia M.; Jackson, Sam; Heyward, William L.; Janssen, Robert S.
Journal:
Vaccine
Issue:
Volume 33:Issue 31(2015)
Page Start:
3614
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗